Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Global Forecast 2024-2030
The Antibody Drug Conjugate Market size was estimated at USD 5.60 billion in 2023 and expected to reach USD 6.48 billion in 2024, at a CAGR 16.12% to reach USD 15.96 billion by 2030.
The antibody drug conjugate (ADC) includes developing, manufacturing, and commercializing therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissue. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs can be challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.
Regional Insights
The antibody drug conjugates (ADCs) market is evolving in the Americas due to advancements in oncology and the need for targeted therapies. A robust research infrastructure and a favorable environment for innovation encourage growth of ADCs in the Americas. In the European Union (EU), centralized marketing authorization for ADCs is provided by the European Medicines Agency (EMA). The EU has observed several strategic collaborations to develop novel ADC therapy in recent years. The Middle East and Africa region presents untapped potential due to increasing healthcare expenditure and growing awareness of targeted therapies. Increasing R&D expenditure coupled with the prevalence of cancer are raising the need for ADCs in the APAC region. Additionally, introducing and utilizing advanced technologies for manufacturing ADCs is anticipated to increase their adoption by the end-use sectors across the globe.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Antibody Drug Conjugate Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Increasing prevalence of cancer worldwide
- Growth in clinical trial activities and robust product pipeline
- Government support and initiatives encouraging research on cancer
- Market Restraints
- High manufacturing cost of ADC and incidences of product recalls
- Market Opportunities
- Increasing investment in biopharma R&D and introduction of novel ADCs
- Adoption of advanced technologies for developing ADC
- Market Challenges
- Complexity in manufacturing of ADCs
- Market Segmentation Analysis
- Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
- Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
- Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
- Indication: Rapid usage of ADCs for efficient treatment of breast cancer
- End User: Emerging use of ADCs by academic research institutes for novel developments
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antibody Drug Conjugate Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antibody Drug Conjugate Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Lonza to enhance commercial antibody-drug conjugate supply capacity
Lonza has constructed a commercial-scale cGMP filling line at its site in Stein, Switzerland. This initiative aims to enhance Lonza's ability to cater to the bioconjugates and ADC markets. With the introduction of the new filling line, Lonza is capable of manufacturing highly potent antibody drug conjugates (ADCs) and facilitating lyophilization for commercial supply. The construction of the filling line is part of an extended customer agreement, which will support the clinical and commercial supplies of bioconjugates.
ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
ENHERTU is an antibody drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca. It is designed to target HER2 and has been recommended for approval in the European Union for adult patients treatment with advanced non-small cell lung cancer. The development and joint commercialization efforts of Daiichi Sankyo and AstraZeneca have provided the way for patients treated with advanced non-small cell lung cancer with an activating HER2 mutation.
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Pyxis Oncology, a clinical-stage biopharmaceutical company, acquired Apexigen, Inc., a developer of antibody drug conjugates with a focus on innovative oncology therapeutics. This strategic move has positioned the combined company at the forefront of antibody drug conjugate (ADC) innovation. This merger enables Pyxis Oncology to leverage Apexigen's expertise and resources in advancing next-generation therapeutics for the treatment of difficult-to-treat cancers.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antibody Drug Conjugate Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..
Market Segmentation & Coverage
This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:- Mechanism of Action
- CD30 Antibodies
- ErbB2 Antibodies
- Drugs
- Adcetris
- Blenrep
- Enhertu
- Kadcyla
- Padcev
- Trodelvy
- Technology
- Cleavable Linker
- Linkerless
- Non-Cleavable Linker
- Indication
- Blood Cancer
- Breast Cancer
- Lymphoma
- Multiple Myeloma
- Urothelial Cancer & Bladder Cancer
- End User
- Academic Research Institutes
- Biopharmaceutical & Biotechnology Companies
- Hospitals
- Specialized Cancer Centers
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- Alaska
- California
- Florida
- Illinois
- Massachusetts
- Michigan
- Montana
- Nevada
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence of cancer worldwide
- 5.1.1.2. Growth in clinical trial activities and robust product pipeline
- 5.1.1.3. Government support and initiatives encouraging research on cancer
- 5.1.2. Restraints
- 5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
- 5.1.3. Opportunities
- 5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
- 5.1.3.2. Adoption of advanced technologies for developing ADC
- 5.1.4. Challenges
- 5.1.4.1. Complexity in manufacturing of ADCs
- 5.2. Market Segmentation Analysis
- 5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
- 5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
- 5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
- 5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
- 5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
- 5.3. Market Trend Analysis
- 5.3.1. Significant emphasis on securing approval for novel ADC drugs in the Americas
- 5.3.2. Cancer burden coupled with improving healthcare infrastructure in the APAC region
- 5.3.3. Supportive government initiatives for improved cancer research and treatment in the EMEA region
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Antibody Drug Conjugate Market, by Mechanism of Action
- 6.1. Introduction
- 6.2. CD30 Antibodies
- 6.3. ErbB2 Antibodies
- 7. Antibody Drug Conjugate Market, by Drugs
- 7.1. Introduction
- 7.2. Adcetris
- 7.3. Blenrep
- 7.4. Enhertu
- 7.5. Kadcyla
- 7.6. Padcev
- 7.7. Trodelvy
- 8. Antibody Drug Conjugate Market, by Technology
- 8.1. Introduction
- 8.2. Cleavable Linker
- 8.3. Linkerless
- 8.4. Non-Cleavable Linker
- 9. Antibody Drug Conjugate Market, by Indication
- 9.1. Introduction
- 9.2. Blood Cancer
- 9.3. Breast Cancer
- 9.4. Lymphoma
- 9.5. Multiple Myeloma
- 9.6. Urothelial Cancer & Bladder Cancer
- 10. Antibody Drug Conjugate Market, by End User
- 10.1. Introduction
- 10.2. Academic Research Institutes
- 10.3. Biopharmaceutical & Biotechnology Companies
- 10.4. Hospitals
- 10.5. Specialized Cancer Centers
- 11. Americas Antibody Drug Conjugate Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Antibody Drug Conjugate Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Antibody Drug Conjugate Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2023
- 14.2. FPNV Positioning Matrix, 2023
- 14.3. Competitive Scenario Analysis
- 14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
- 14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
- 14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
- 14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
- 14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
- 14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
- 14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
- 14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
- 14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
- 14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
- 14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.2. Key Product Portfolio
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook